Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Sintilimab, Bevacizumab Biosimilar, and TACE-HAIC for HCC with PVTT
NCT06031285Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Recurrence-Free Survival at 6 months. Started Sep 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06031285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031285.